<code id='B7E6F7BF7B'></code><style id='B7E6F7BF7B'></style>
    • <acronym id='B7E6F7BF7B'></acronym>
      <center id='B7E6F7BF7B'><center id='B7E6F7BF7B'><tfoot id='B7E6F7BF7B'></tfoot></center><abbr id='B7E6F7BF7B'><dir id='B7E6F7BF7B'><tfoot id='B7E6F7BF7B'></tfoot><noframes id='B7E6F7BF7B'>

    • <optgroup id='B7E6F7BF7B'><strike id='B7E6F7BF7B'><sup id='B7E6F7BF7B'></sup></strike><code id='B7E6F7BF7B'></code></optgroup>
        1. <b id='B7E6F7BF7B'><label id='B7E6F7BF7B'><select id='B7E6F7BF7B'><dt id='B7E6F7BF7B'><span id='B7E6F7BF7B'></span></dt></select></label></b><u id='B7E6F7BF7B'></u>
          <i id='B7E6F7BF7B'><strike id='B7E6F7BF7B'><tt id='B7E6F7BF7B'><pre id='B7E6F7BF7B'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:885
          Adobe

          By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies.

          Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023. Each of the three niches continue to generate buzz among investors, even as other areas fizzle.

          advertisement

          It’s not that those three industries are perfect fits for private equity, it’s that the more obvious areas like autism therapists and physician practices are struggling with high interest rates and regulatory scrutiny, said Rebecca Springer, PitchBook’s lead health care analyst.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates
          Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

          DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          Was Amgen transparent enough on FDA's concern on cancer drug?

          MarkJ.Terrill/APAmidthestunningrebukeAmgensufferedatthehandsoftheU.S.FoodandDrugAdministrationthiswe